Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 4Triple Negative Breast Neoplasms 3Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Cancer Patients 1Pancreatic Neoplasms 1Locally Advanced Rectal Cancer 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Cisplatin 4trastuzumab deruxtecan 3Platinum 3Docetaxel 3Carboplatin 3Biopsy 3entrectinib 2darolutamide 2Trastuzumab 2Radiotherapy, Intensity-Modulated 2Leuprolide 2Goserelin 2Ado-Trastuzumab Emtansine 21,2-diaminocyclohexaneplatinum II citrate 2zanidatamab 1trastuzumab biosimilar HLX02 1sacituzumab govitecan 1pyrotinib 1pertuzumab 1pembrolizumab 1luprolide acetate gel depot 1larotrectinib 1enfortumab vedotin 1dehydroftorafur 1ceralasertib 1camrelizumab 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Salivary Gland Neoplasms × camrelizumab × 90 days × Clear all
NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡